GDF15 antibody (C-Term)

Catalog No. ABIN453961

The Rabbit Polyclonal anti-GDF15 antibody has been validated for WB and EIA. It is suitable to detect GDF15 in samples from Human, Mouse, Rat, Chimpanzee and Macaque.

Quick Overview for GDF15 antibody (C-Term) (ABIN453961)

Target: GDF15 (Growth Differentiation Factor 15 (GDF15))

Reactivity: Human, Mouse, Rat, Chimpanzee, Macaque

Host: Rabbit

Clonality: Polyclonal

Conjugate: This GDF15 antibody is un-conjugated

Application: Western Blotting (WB), Enzyme Immunoassay (EIA)

Product Details anti-GDF15 Antibody

Binding Specificity: C-Term

Specificity: This antibody reacts with the C-terminus of endogenous NAG-1 protein.

Cross-Reactivity (Details): Species reactivity (expected):Chimpanzee, Macaque, Mouse, Rat.
Species reactivity (tested):Human.

Purification: Affinity chromatography

Immunogen: Synthetic peptide corresponding to the C-terminal sequence of NAG-1 protein. A residue of cysteine was added to facilitate coupling

Isotype: IgG

Application Details

Application Notes: ELISA: 1/300,000. Western Blot: 2,000 - 10,000.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1.0 mg/mL (by UV absorbance at 280 nm)

Buffer: 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2 containing 0.09 % (w/v) Sodium

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Avoid repeated freezing and thawing.

Storage: -20 °C

Target Details for GDF15

Target: GDF15 (Growth Differentiation Factor 15 (GDF15))

Alternative Name: GDF15

Background: The non-steroidal antiinflammatory drug (NSAID) activated gene (NAG-1) is a member of the transforming growth factor-beta (TGF-beta) superfamily. NAG-1 is also known as Macrophage Inhibitory Cytokine-1 (MIC-1), Growth Differentiation Factor 15 (GDF15), Placental Bone Morphogenetic Protein (PLAB), or Prostate Derived Factor (PDF). NAG-1 is expressed in human placenta, prostate and colon. It possesses antitumorigenic and proapoptotic activities. NAG-1 expression is dramatically increased in inflammation, injury and malignancy. Increase of NAG-1 expression is a feature of many cancers including breast, colon, pancreas and prostate. In a number of studies, NAG-1 expression was increased by a number of NSAIDs. This increase in expression may correlate with the chemopreventive effect NSAIDs seem to have with certain cancers. NAG-1 expression is also induced by PPAR gamma ligands and by several dietary compounds such as conjugated linoleic acids (CLAs), naturally occurring fatty acids in ruminant food products, indoles, epicatechin gallate, and genistein. The induced expression of NAG-1 results in a stimulation of apoptosis and inhibition of cell growth. Inhibition of NAG-1 induced expression by small interference RNA (siRNA) results in repression of induced apoptosis. NAG-1 expression is regulated by a numbers of transcription factors such as ERG-1 and Sp1. EGR-1 may be necessary for NSAID-induced NAG-1 expression. The study of expression of NAG-1 proteins, including variants, is important to define their potential role as serum biomarkers for cancer diagnosis, treatment monitoring, epidemiology study, and nutrition surveys.Synonyms: GDF-15, Growth/differentiation factor 15, MIC-1, MIC1, Macrophage inhibitory cytokine 1, NAG-1, NRG-1, NSAID-activated gene 1 protein, NSAID-regulated gene 1 protein, PDF, PLAB, PTGFB, Placental TGF-beta, Placental bone morphogenetic protein, Prostate differentiation factor

Gene ID: 9518

NCBI Accession: NP_004855

UniProt: Q99988

Pathways: SARS-CoV-2 Protein Interactome